Office Address:
1161 21st Avenue South, Preston Research Building, Room / Suite D-3100 Medical Center North, Nashville, TN 37232

Cornelius Abernathy Craig Professor, Medicine and Biochemistry

Interim Chair, Department of Medicine

Interim Physician in Chief, Vanderbilt Hospital

Hometown
Sheffield, IA
Previous Institution
University of North Carolina at Chapel Hill
Previous Role/Title
Associate Professor of Medicine
Specialty
Oncology/Urology

Education

MD - Stanford University, Stanford, California, 1998
PhD - Stanford University, Stanford, California, 1996
BA - University of Northern Iowa, Cedar Falls, Iowa, 1991
BS - University of Northern Iowa, Cedar Falls, Iowa, 1991

Postgraduate Training

Internship

University of Chicago Medical Center, 1999

Fellowship

Hematology/Oncology - University of Pennsylvania, 2003

Board and Certifications

Medical Oncology - American Board of Internal Medicine, 2004

Professional Highlights

As the Director of the Division of Hematology and Oncology, I am invested in creating a basic, translational, and clinical program that supports each of our cancer programs.

As a genitourinary oncologist, I focus on renal cell carcinoma. Our laboratory is focused on cancers caused by deregulation of the normal hypoxia response pathway. We use clear cell renal cell carcinoma as a model system because virtually all of these tumors display dysregulation of this pathway. This cancer affects over 60,000 new patients annually in the US. Recent molecular discoveries based on understanding the hypoxia response pathway have led to the development of multiple new lines of treatment for this cancer. Our goal is to identify strategies to improve the treatment of cancers dependent on hypoxia pathway activation, or better ways to detect these cancers earlier. Therefore, our research takes a broad approach using genetic techniques to study tumor-initiating events and events that promote the development of invasive or metastatic features using in vitro, animal, and human systems. This translational research, all geared toward enhancing our understanding of the genetics and molecular biology of hypoxia-driven cancers, is folded into a clinical research program at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center.

Clinical Interest

As a genitourinary oncologist, I focus on renal cell carcinoma.

Areas of Expertise

Cancer
Genetics
Medical Oncology
Prostate, Bladder, and Kidney Cancer
Urologic/Genitourinary Cancer

Location

Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
2220 Pierce Avenue
Nashville, TN 37232
(map)
Research Keywords
Renal cell carcinoma
Research Description

Our laboratory is focused on cancers caused by deregulation of the normal hypoxia response pathway. We use clear cell renal cell carcinoma as a model system because virtually all of these tumors display dysregulation of this pathway. This cancer affects over 60,000 new patients annually in the US. Recent molecular discoveries based on understanding the hypoxia response pathway have led to the development of multiple new lines of treatment for this cancer. Our goal is to identify strategies to improve the treatment of cancers dependent on hypoxia pathway activation, or better ways to detect these cancers earlier. Therefore, our research takes a broad approach using genetic techniques to study tumor-initiating events and events that promote the development of invasive or metastatic features using in vitro, animal, and human systems. This translational research, all geared toward enhancing our understanding of the genetics and molecular biology of hypoxia-driven cancers, is folded into a clinical research program at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center.